|
Scancell Holdings PLC on Monday said it has partnered with the NHS Cancer Vaccine Launch Pad, to accelerate patient recruitment into the fourth cohort of its phase 2 scope study for a targeted melanoma vaccine. Scancell shares were up 19% at 9.79 pence in London on Monday afternoon. The Oxford-based pharmaceutical firm said the collaboration will provide faster access for NHS patients with advanced unresectable melanoma to its investigational iSCIB1+ cancer vaccine, which is being tested alongside standard immunotherapy. The trial will evaluate intradermal delivery of iSCIB1+, a second-generation, DNA-based Immunobody vaccine designed to stimulate a strong and lasting immune response. Scancell said it expects the first patients to be referred from May, and that NHS hospitals across the UK will participate in the study. Recent clinical data, Scancell added, showed the vaccine’s potential to deliver ‘meaningful long-term survival benefits.’ Chief Medical Officer Nermeen Varawalla said the partnership ‘is an important step in accelerating the clinical development of this important new treatment’. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
